CN-121695128-B - Use of PHANGININ A in preparing medicine for preventing and/or treating skin diseases

Abstract

The invention belongs to the technical field of medicines, and particularly provides an application of PHANGININ A in preparing a medicine for preventing and/or treating skin diseases. The skin diseases include atopic dermatitis and skin epidermis barrier damage. The invention discovers PHANGININ A that the skin damage score of the atopic dermatitis can be reduced, the pathological thickening and inflammatory cell infiltration of the skin of the atopic dermatitis can be improved, the inflammatory reaction of spleen can be reduced, the volume increase can be restrained, the thymus function recovery can be promoted, the expression of inflammatory factors IL-6 and TNF-alpha related to the atopic dermatitis can be reduced, and the invention can be used for preventing and/or treating the atopic dermatitis. In addition, PHANGININ A can promote the healing of the keratinocyte scarification and can be used for repairing the skin epidermis barrier injury.

Inventors

• SU JIA
• Ding Linfen
• YANG LING
• WU XINGDE
• Tu Wenchao

Assignees

• 云南中医药大学
• 昆明医科大学

Dates

Publication Date

20260512

Application Date

20260212

Claims (8)

1. Use of phangin a or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of atopic dermatitis.
2. 2. The use according to claim 1, wherein the medicament is for repairing damage to the epidermal barrier of the skin.
3. 3. The use according to claim 1, wherein the medicament reduces the atopic dermatitis skin damage score, improves the pathological thickening of the atopic dermatitis skin and the skin inflammatory cell infiltration, reduces the spleen inflammatory reaction, inhibits its volume increase, promotes the recovery of thymus function.
4. 4. The use according to claim 1, wherein the medicament down regulates the expression of inflammatory factors IL-6 and TNF- α associated with atopic dermatitis.
5. 5. The use according to claim 1, wherein the medicament promotes healing of keratinocyte lesions.
6. 6. The use according to claim 1, wherein PHANGININ A or a pharmaceutically acceptable salt thereof is used in a dose of 6.09 to 12.19 mg/kg by weight.
7. 7. The use according to any one of claims 1 to 6, wherein the medicament further comprises pharmaceutically acceptable pharmaceutical excipients.
8. 8. The use according to any one of claims 1 to 6, wherein the pharmaceutical dosage form is a tablet, capsule, granule, injection, oral liquid, pill, paste, suspension, dispersion, syrup, suppository, gel, aerosol or patch.

Description

Use of PHANGININ A in preparing medicine for preventing and/or treating skin diseases Technical Field The invention belongs to the technical field of medicines, and particularly relates to an application of PHANGININ A in preparing medicines for preventing and/or treating skin diseases, in particular to an application in preparing medicines for treating atopic dermatitis and skin epidermis barrier injury repair. Background The skin is the largest organ of human body, and has a plurality of important functions of protecting, excreting, regulating body temperature, feeling external stimulus and the like. However, the skin is also susceptible to various factors, leading to the occurrence of various skin diseases such as atopic dermatitis, skin epidermis barrier damage, etc. Atopic dermatitis (Atopic Dermatitis, AD) is a chronic, recurrent, itchy inflammatory skin disease characterized by a central pathological condition of skin barrier dysfunction, immune dysfunction and neurosensory abnormalities. It is typically manifested clinically as polymorphic lesions such as erythema, papules, exudative eczematoid lesions, lichenification and severe itching, often accompanied by dry skin and high reactivity (itching-scratching vicious circle). AD onset presents a significant bimodal distribution of age, with 60% of cases onset in infancy, 30% lasting to adulthood. Global morbidity increases 2-3 fold over the last 20 years, now becoming the top-ranked health problem for disease burden in non-lethal disease. AD pathogenesis is complex involving multidimensional interactions. Including ① genetic susceptibility, about 30% of patients have filaggrin due to mutation of the filaggrin gene, disruption of the physical barrier of the skin, and Th2/Th22/Th17 (helper T cells, T HELPER CELL, th) immune pathway-related gene polymorphism driving immune imbalance. ② Immune-barrier-microorganism axis disorder, epidermal barrier injury promotes allergen penetration, triggers type 2 inflammation (interleukin-4/interleukin-13) and neuroimmune activation (interleukin-33, nerve growth factor mediated itching signal), and staphylococcus aureus colonization further aggravates inflammation. ③ Environmental and neuropsychological factors, climate change, pollutants, psychological stress affect disease progression through epigenetic modification. AD patients often combine allergic diseases (asthma, allergic rhinitis, food allergy) and immunodeficiency states, and the risk of anxiety, depression and sleep disorders is significantly increased due to chronic itching, constituting a multidimensional health burden. Based on this, there is a need for a safe and effective therapeutic pharmaceutical formulation for atopic dermatitis. PHANGININ A is a kashan alkane diterpenoid compound, which has been proved to have various biological activities. The active salt is an effective oral active salt induced kinase 1 (SIK 1) activator, and can achieve the effects of promoting skeletal muscle glucose uptake, reducing blood sugar level and improving glucose tolerance and dyslipidemia by inhibiting gluconeogenesis, increasing p-SIK1 expression and reducing p-CREB expression, thereby having the potential of treating type 2 diabetes. At present, no SIK1 is reported as a drug target for atopic dermatitis, no SIK1 activator is reported for inhibiting the atopic dermatitis, and no PHANGININ A is reported for treating the atopic dermatitis and the damage of the skin epidermis barrier. Disclosure of Invention Aiming at the problems in the prior art, the invention provides the application of PHANGININ A in preparing medicaments for preventing and/or treating skin diseases, in particular to the application in preparing medicaments for treating atopic dermatitis and skin epidermis barrier injury repair. The invention is realized by the following technical scheme: First, the present invention provides use of PHANGININ A or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention and/or treatment of a skin disorder. PHANGININ A is derived from Caesalpinia sappan of Leguminosae, is a kashan alkane diterpenoid compound, has CAS number of 1011528-58-7, molecular formula of C 21H28O5, and chemical structural formula shown as follows: Preferably, the pharmaceutically acceptable salts include at least one of lithium, potassium, sodium salts with alkali metals, calcium, magnesium salts with alkaline earth metals, hydrochloride, sulfate, phosphate salts with inorganic acids, tartrate, maleate, succinate, citrate, p-toluenesulfonate, butyrate, camphorsulfonate, methanesulfonate salts with organic acids. Preferably, the skin disorder includes atopic dermatitis and skin epidermis barrier damage. Preferably, the medicament can reduce the skin damage score of the atopic dermatitis, improve the pathological thickening of the skin of the atopic dermatitis and the inflammatory cell infiltration of the skin, reduce the inflammatory reaction of spleen,